Infliximab Articles
US HMOs reveal their most-accepted drugs
5 April 2001
S-P takes Australian PBAC to court
23 March 2001
Remicade has promise in psoriasis, says J&J
8 March 2001
Immunex drops plans to develop Enbrel for Crohn's disease
14 February 2001
EU extends Remicade indications
7 February 2001
J&J sales up despite Propulsid problem
24 January 2001
EMEA warns on Remicade risks
4 January 2001
New work program for NICE announced
20 November 2000
FDA to strengthen warnings on Enbrel and Remicade?
2 November 2000
Remicade gains broader label for RA
26 October 2000
Johnson & Johnson earnings climb 14%
18 October 2000
Schering-Plough sees desloratadine backing
12 October 2000
J&J beats forecasts with 2nd qtr earnings
20 July 2000
Remicade OKed in EU for rheumatoid arthritis
5 July 2000
Remicade approved for RA in the UK
29 June 2000
Johnson & Johnson net earnings rise 15.5%
19 April 2000
Unstable angina, IBD market forecasts
15 February 2000
Enbrel selling at $500 million per year
6 December 1999
Celltech Chiroscience to file for CDP571 approval in 2000
23 November 1999
Centocor files for RA Remicade indication
21 October 1999
Stock Commentary New York
23 September 1999
Centocor unblinds Remicade RA trial
22 September 1999
Dynavax looks to IPO in 2000 to progress DNA immunization
16 September 1999
Isis reacquires Crohn's drug, plans filing in early 2000
9 September 1999
Centocor's Remicade OKed in Europe
19 August 1999
Centocor expects Remicade decision in November
17 August 1999
Stock Commentary New York
1 July 1999
One-year RA data for Centocor's Remicade
9 June 1999
CPMP backs Remicade for Crohn's
24 May 1999
Centocor files for Remicade in arthritis
27 January 1999
Celltech Makes Solid Six-Month Progress
16 December 1998
Immunex Hit By Analyst Report On Enbrel Side Effects
16 December 1998
Stock Commentary New York
26 November 1998
Centocor Shares Fall As Remicade Warning Goes Out
23 November 1998
Remicade Effective In Rheumatoid Arthritis
11 November 1998
Goldman Sachs, MSDW Top II's 1998 Analysts List
10 November 1998
Remicade Now Available For Crohn's In First Market
15 October 1998
The Emerging Role Of Anticytokine Therapy
1 October 1998
Enbrel Recommended For Approval By US Panel
21 September 1998
FDA Approves Remicade For Crohn's Disease
25 August 1998
Solid Growth Forecast For Schering Plough
24 August 1998
Infliximab "complete review" letter
2 July 1998
Stock Commentary New York
18 June 1998
FDA Panel Backs Centocor's Avakine For Crohn's
4 June 1998
FDA Panel Backs Centocor's Avakine For Crohn's
1 June 1998
CellTech Makes Solid Six-Month Progress
19 May 1998
S-P Licenses Avakine From Centocor
8 April 1998
FDA To Fast-Track Centocor's Avakine
5 March 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
Centocor Files BLA For Avakine
2 January 1998
Centocor Still Looking For Avakine Deal
18 December 1997
ReoPro Sales To Reach $240 Million In 1997
11 December 1997
Stock Commentary New York
13 November 1997
Centocor's Avakine, Efficacy In RA?
13 November 1997
Centocor To Report ReoPro Data In MI
6 November 1997
Centocor's Avakine Effective In Crohn's
16 October 1997
Centocor Reveals Positive cA2 Data
19 May 1997
New York Stock Comment
12 May 1997
New York Stock Comment
5 May 1997
US Quarterly Financial Results Round-Up
5 May 1997
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
